Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 2/20 | 0.54 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | POLR1A | O95602 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566343 | 1.00 | IL1B (0.54) | IL1BMALT1HRH3ACHEPOLR1A | |
| SCHEMBL22654933 | 0.71 | IL1B (1.00) | IL1B | |
| SCHEMBL22655089 | 0.70 | ACHE (0.67) | IL1BHRH3ACHEALDH1A1RAB9A | |
| SCHEMBL22655091 | 0.70 | ACHE (0.67) | IL1BHRH3ACHEALDH1A1RAB9A | |
| SCHEMBL22639887 | 0.69 | SIGMAR1 (0.55) | MAPTALDH1A1GAANPC1RAB9A | |
| SCHEMBL29566823 | 0.68 | ACHE (0.46) | IL1BHRH3ACHE | |
| SCHEMBL22655110 | 0.68 | ACHE (0.46) | IL1BHRH3ACHE | |
| SCHEMBL21610612 | 0.67 | MALT1 (0.37) | IL1BMALT1POLR1A | |
| SCHEMBL22010188 | 0.67 | MALT1 (0.37) | IL1BMALT1POLR1A | |
| SCHEMBL18256577 | 0.67 | MALT1 (0.37) | IL1BMALT1POLR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885MALT1 3486/4885HRH3 453/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885MALT1 3486/4885HRH3 453/4885 |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885MALT1 3486/4885HRH3 453/4885 |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885MALT1 3486/4885HRH3 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.